2-Arylthiazolidine-4-carboxylic acid amides (ATCAA) target dual pathways in cancer cells: 5′-AMP-activated protein kinase (AMPK)/mTOR and PI3K/Akt/mTOR pathways

International Journal of Oncology

Volumn 37, Issue 4, 2010, Pages 1023-1030

  Li, Chien Ming ^a,b   Narayanan, Ramesh ^a   Lu, Yan ^c   Hurh, Eunju ^b   Coss, Christopher C ^a   Barrett, Christina M ^a   Miller, Duane D ^a,c   Dalton, James T ^a,b  

^a GTx Inc   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

2 arylthiazolidine 4 carboxylic acid amides; AMP activated protein kinase; Pharmacokinetics; PI3k Akt mTOR; Xenograft

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 ARYLTHIAZOLIDINE 4 CARBOXYLIC ACID AMIDE 10; 5' AMP ACTIVATED PROTEIN LINASE; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR; GLUCOSE; GLYCOPROTEIN P; INSULIN; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE B; PROTEIN SERINE THREONINE KINASE; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG;

AMPLICON; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RESISTANCE; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INACTIVATION; ENZYME PHOSPHORYLATION; GLUCOSE BLOOD LEVEL; HELA CELL; HUMAN; HUMAN CELL; HYPERGLYCEMIA; HYPERINSULINEMIA; IC 50; INSULIN BLOOD LEVEL; LUNG ADENOCARCINOMA; MALE; MOUSE; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN TARGETING; RAT; SINGLE DRUG DOSE; TUMOR XENOGRAFT;

EID: 77956538052     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000754     Document Type: Article

References (27)

1. Engelman JA, Luo J and Cantley LC: The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 7: 606-619, 2006. (Pubitemid 44100518)
2. Wymann MP, Zvelebil M and Laffargue M: Phosphoinositide 3-kinase signalling - which way to target? Trends Pharmacol Sci 24: 366-376, 2003.
3. Feng J, Park J, Cron P, Hess D and Hemmings BA: Identification of a PKB/Akt hydrophobic motif Ser-473 kinase as DNA-dependent protein kinase. J Biol Chem 279: 41189-41196, 2004.
4. Vivanco I and Sawyers CL: The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2: 489-501, 2002.
5. Grunwald V, De Graffenried L, Russel D, Friedrichs WE, Ray RB and Hidalgo M: Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. Cancer Res 62: 6141-6145, 2002.
6. Cohen P and Frame S: The renaissance of GSK3. Nat Rev Mol Cell Biol 2: 769-776, 2001.
7. Frame S and Cohen P: GSK3 takes centre stage more than 20 years after its discovery. Biochem J 359: 1-16, 2001.
8. Dan HC, Sun M, Yang L, et al: Phosphatidylinositol 3-kinase/ Akt pathway regulates tuberous sclerosis tumor suppressor complex by phosphorylation of tuberin. J Biol Chem 277: 35364-35370, 2002.
9. Mita MM, Mita A and Rowinsky EK: The molecular target of rapamycin (mTOR) as a therapeutic target against cancer. Cancer Biol Ther 2: S169-S177, 2003.
10. Gunn RM and Hailes HC: Insights into the PI3-K-PKB-mTOR signalling pathway from small molecules. J Chem Biol 1: 49-62, 2008.
11. Hardie DG and Carling D: The AMP-activated protein kinase-fuel gauge of the mammalian cell? Eur J Biochem 246: 259-273, 1997.
12. Woods A, Johnstone SR, Dickerson K, et al: LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. Curr Biol 13: 2004-2008, 2003.
13. Hardie DG, Salt IP, Hawley SA and Davies SP: AMP-activated protein kinase: an ultrasensitive system for monitoring cellular energy charge. Biochem J 338: 717-722, 1999.
14. Kemp BE, Stapleton D, Campbell DJ, et al: AMP-activated protein kinase, super metabolic regulator. Biochem Soc Trans 31: 162-168, 2003.
15. Inoki K, Zhu T and Guan KL: TSC2 mediates cellular energy response to control cell growth and survival. Cell 115: 577-590, 2003. (Pubitemid 37506046)
16. Kimura N, Tokunaga C, Dalal S, et al: A possible linkage between AMP-activated protein kinase (AMPK) and mammalian target of rapamycin (mTOR) signalling pathway. Genes Cells 8: 65-79, 2003.
17. Luo Z, Saha AK, Xiang X and Ruderman NB: AMPK, the metabolic syndrome and cancer. Trends Pharmacol Sci 26: 69-76, 2005.
18. Hadad SM, Fleming S and Thompson AM: Targeting AMPK: a new therapeutic opportunity in breast cancer. Crit Rev Oncol Hematol 67: 1-7, 2008.
19. Motoshima H, Goldstein BJ, Igata M and Araki E: AMPK and cell proliferation - AMPK as a therapeutic target for atherosclerosis and cancer. J Physiol 574: 63-71, 2006.
20. Lu Y, Wang Z, Li CM, et al: Synthesis, in vitro structureactivity relationship, and in vivo studies of 2-arylthiazolidine-4- carboxylic acid amides as anticancer agents. Bioorg Med Chem 18: 477-495, 2010.
21. Crouthamel MC, Kahana JA, Korenchuk S, et al: Mechanism and management of AKT inhibitor-induced hyperglycemia. Clin Cancer Res 15: 217-225, 2009.
22. Traunecker HC, Stevens MC, Kerr DJ and Ferry DR: The acridonecarboxamide GF120918 potently reverses P-glycoprotein- mediated resistance in human sarcoma MES-Dx5 cells. Br J Cancer 81: 942-951, 1999.
23. Hoffman K, Holmes FA, Fraschini G, et al: Phase I-II study: triciribine (tricyclic nucleoside phosphate) for metastatic breast cancer. Cancer Chemother Pharmacol 37: 254-258, 1996.
24. 2+/calmodulin-dependent protein kinase kinases are AMP-activated protein kinase kinases. J Biol Chem 280: 29060-29066, 2005.
25. King TD, Song L and Jope RS: AMP-activated protein kinase (AMPK) activating agents cause dephosphorylation of Akt and glycogen synthase kinase-3. Biochem Pharmacol 71: 1637-1647, 2006.
26. Rattan R, Giri S, Singh AK and Singh I: 5-Aminoimidazole-4- carboxamide-1-beta-D-ribofuranoside inhibits cancer cell proliferation in vitro and in vivo via AMP-activated protein kinase. J Biol Chem 280: 39582-39593, 2005.
27. Hahn-Windgassen A, Nogueira V, Chen CC, Skeen JE, Sonenberg N and Hay N: Akt activates the mammalian target of rapamycin by regulating cellular ATP level and AMPK activity. J Biol Chem 280: 32081-32089, 2005.